A Phase I Study to Investigate the Absorption, Pharmacokinetics, and Excretion of [(14)C]Prucalopride After a Single Oral Dose in Healthy Volunteers.
Chronic constipation is a prevalent gastrointestinal disorder globally. It is often treated with medications such as laxatives. Newer therapies to improve gastric motility include the selective 5-hydroxytryptamine receptor-4 agonist prucalopride, which is licensed for the treatment of chronic constipation in adults. The aim of this study was to investigate the pharmacokinetic properties and excretion of prucalopride in healthy individuals, using a microtracer approach with (14)C radioactivity detection using liquid scintillation counting and accelerator mass spectrometry.



This was a single-period, open-label, nonrandomized absorption, metabolism, and excretion study of [(14)C]prucalopride. Participants were 6 healthy men aged 18 to 50 years. After screening, participants were administered a single dose of [(14)C]prucalopride succinate 2 mg (~200 nCi). Postadministration, urine, feces, and blood samples were collected over a 10-day period. Safety and adverse event data were also collected.



Almost 100% of the administered dose of radioactivity was recovered, with a mean (SD) of 84.2% (8.88%) recovered in urine and 13.3% (1.73%) recovered in feces. The mean blood-to-plasma concentration ratio of 1.9 indicated uptake of prucalopride into blood cells. The renal clearance of prucalopride was 17.0 (2.5) L/h, which is higher than the glomerular filtration rate in healthy individuals, suggesting active renal transport of prucalopride. Prucalopride was well tolerated, with no serious adverse events reported.



Prucalopride was well absorbed and excreted mainly by the kidneys, including both passive and active transporter mechanisms. Quantitative recovery of the radioactive dose was achieved. Consistent with previous studies, prucalopride was generally well tolerated. ClinicalTrials.gov identifier: NCT01807000.
Covance Laboratories, Madison, Wisconsin. Electronic address: stephen.flach@covance.com.
Stephen
S
Flach
Shire Pharmaceuticals Ltd, Chineham, Basingstoke, Hampshire, United Kingdom.
Graeme
G
Scarfe
Shire Pharmaceuticals Inc, Lexington, Massachusetts.
Jeffrey
J
Dragone
Covance Laboratories, Madison, Wisconsin.
Jie
J
Ding
Xceleron, Germantown, Maryland.
Mark
M
Seymour
Shire Pharmaceuticals Ltd, Chineham, Basingstoke, Hampshire, United Kingdom.
Mike
M
Pennick
Xceleron, Germantown, Maryland.
Todd
T
Pankratz
Shire Pharmaceuticals Inc, Lexington, Massachusetts.
Steven
S
Troy
Shire Pharmaceuticals Inc, Lexington, Massachusetts.
Jay
J
Getsy
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D001572:Benzofurans / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D002250:Carbon Radioisotopes; D005243:Feces / Q000737:chemistry; D064368:Healthy Volunteers; D006801:Humans; D007408:Intestinal Absorption; D054368:Laxatives / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D008297:Male; D008875:Middle Aged; D055815:Young Adult
D001572:Benzofurans; D002250:Carbon Radioisotopes; D054368:Laxatives; C406662:prucalopride
chronic constipation; excretion; microtracer study; pharmacokinetics; prucalopride